The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The facility is expected to be completed in 2024
Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India
The government has taken all the effective measures to make healthcare affordable
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
Subscribe To Our Newsletter & Stay Updated
